Larsen will present the study, «Short and Long - Term Risk of Congestive Heart Failure in Breast Cancer and
Lymphoma Patients Compared to Controls: an Epidemiologic Study,» on Saturday, March 10.
Not exact matches
«We found very high response rates to this treatment combination, which has the added benefit of having a much reduced risk of long - term organ damage
compared to the highly toxic chemotherapy agents typically used for
patients with relapsed Hodgkin
lymphoma,» says Dr. Kelly, who is Program Director of the Pediatric Hematology / Oncology Service Line at the Women & Children's Hospital of Buffalo and holds an additional faculty appointment with the University at Buffalo.
Patients with a history of breast cancer or lymphoma were more than three times as likely to develop heart failure — a condition in which the heart can't pump enough blood to meet the body's needs — compared with a similar group of patients who did not have cancer, according to data being presented at the American College of Cardiology's 67th Annual Scientific
Patients with a history of breast cancer or
lymphoma were more than three times as likely to develop heart failure — a condition in which the heart can't pump enough blood to meet the body's needs —
compared with a similar group of
patients who did not have cancer, according to data being presented at the American College of Cardiology's 67th Annual Scientific
patients who did not have cancer, according to data being presented at the American College of Cardiology's 67th Annual Scientific Session.
People with breast cancer or
lymphoma were three times as likely to develop heart failure within five years of their cancer diagnosis, and 20 years following cancer treatment were still nearly twice as likely to have been diagnosed with heart failure
compared to similar
patients who didn't undergo cancer therapy.
Researchers then
compared patients in the trial to 151 similar
patients who did not have HIV but received the same treatment for their
lymphoma using data reported to the Center for International Blood & Marrow Transplant Research (CIBMTR).
However, in this Phase II clinical trial, designed to prospectively evaluate the safety and effectiveness of ACHT for
patients with HIV - related
lymphoma, researchers discovered that this population had no greater likelihood of developing these complications
compared to those without the virus.
CHOP Chemotherapy Plus Rituximab
Compared With CHOP Alone In Elderly
Patients With Diffuse Large B - Cell
Lymphoma
Compared with the United States cancer populations, trials of
lymphoma, CLL, CML, and myeloma enrolled a disproportionately higher percentage of
patients younger than 65 years.
These
patients were significantly underrepresented in trials of new treatments for
lymphoma, CLL, and myeloma
compared with the incidence of these diseases in that age group.
The use of anti-CD19 chimeric antigen receptor T cells induced a nearly sixfold higher rate of complete response
compared with historical outcomes in
patients with refractory, aggressive non-Hodgkin
lymphoma.